Right. Since it's essentially an add-on product sold amd promoted through the same channel, with the needle's advantages at a competitive price, and coming from a manufacturer the end user already trusts, there's a high likelyhood they can capture most of the F60 patients as users of the needle as well. I have no idea on the pricing. If they charge USD 5 per infusion (remember the average user may need several needles per infusion), this would over time double the recurring revenue stream per patient. Not sure how fast we'll see this though. The patients might first use up their supply of old needles before they get the Hi Flow.
News 
Market Data 
Discover 
AI
